NanoVibronix shares surge 15.74% premarket as company rebrands to ENvue Medical, focusing on ENvue feeding tube system's multi-billion-dollar market potential.

NanoVibronix (NASDAQ: NAOV) surged 15.74% in premarket trading following its announcement to rebrand as ENvue Medical and shift strategic focus to its FDA-cleared ENvue feeding-tube placement system. The company emphasized ENvue as its core growth platform, highlighting its real-time navigation capabilities in enteral feeding and potential expansion into pediatric, vascular, and robotic applications. The rebranding, accompanied by a planned NASDAQ ticker change, signals a pivot toward a $1.8 billion U.S. market opportunity by 2030. Management also outlined a roadmap to scale hospital adoption, strengthen commercial operations, and explore partnerships or divestitures for legacy assets like PainShield and UroShield. The move underscores renewed investor confidence in the company’s clinical innovation and market scalability.